Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Advanced Solid Tumours
Interventions: Ceralasertib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Prostate Cancer
Interventions: Focal therapy; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma
Interventions: MVA-BN-Brachyury; Combination Product
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions: Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Prostate Cancer
Interventions: An MRI-based technique to identify prostate cancer; Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
Interventions: Talazoparib, Belinostat; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Intervention Session, Printed Material; Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Las Vegas, Nevada • New York, New York

Conditions: Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Gynecologic Cancer, Gastrointestinal Cancer
Interventions: Survey, Saliva sample, Smoking Status questions; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: FT-7051; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Prostate Cancer Metastatic
Interventions: Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more

Conditions: Prostate Cancer
Interventions: Degarelix, Goserelin acetate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 36
States / cities: Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 32 more

Conditions: Prostate Cancer
Interventions: Pacritinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostatic Neoplasms
Interventions: PROSTVAC-V/F; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Prostatic Neoplasms
Interventions: EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone, Apalutamide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Towson, Maryland • Omaha, Nebraska • Myrtle Beach, South Carolina

Conditions: Prostate Cancer
Interventions: Bi-parametric MRI-based cascaded deep-learning AI algorithm; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 40 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month and older
Enrollment: 19,522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Trimethoprim Tablets; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: PSA, Prostate Cancer
Interventions: MRI prostate; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions: Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest; Drug · Device · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
Interventions: EU101; Drug
Lead sponsor: Eutilex; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Castrate-Resistant Prostate Cancer
Interventions: Atezolizumab, Radium-223 Dichloride; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Duarte, California • San Francisco, California • New Haven, Connecticut + 14 more

Conditions: Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 85 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: Standard of Care MRI, Fluciclovine PET scan added to MRI; Device · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

CUIMC Focal Therapy Registry

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men

Immune Monitoring on Sipuleucel-T

Improving Evidence-Based Care for Cancer Patients

A Study of FT-7051 in Men With MCRPC

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

A Trial of Degarelix in Patients With Prostate Cancer

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

Folate Study in Men With Advanced Prostate Cancer

EDRN Prostate MRI Biomarker Study

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)